Is a
Clinical Study attributes
NCT Number
Trial Recruitment Size
320
Trial Sponsor
Clinical Trial Start Date
November 12, 2024
0Primary Completion Date
May 29, 2026
0Study Completion Date
May 29, 2026
0Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Treatment0
Intervention Type
Drug0
Interventional Trial Phase
Phase 10
Official Name
A Phase 1, Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-6400 in Adult Healthy Volunteers0
Last Updated
October 26, 2024
0Allocation Type
Randomized0
Intervention Model
Parallel Assignment0
Masking Type
Triple0
Masked Party
Investigator0
Care Provider0
Participant0
Other attributes
Intervention Treatment
ALN-64000
Placebo0
Study summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending doses of ALN-6400 in healthy volunteers.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
